Table 1 Participant’s demographics
Parameter | N = 14 | ||||
|---|---|---|---|---|---|
Male sex (%) | 10 (71.4%) | ||||
Age (years) | 55 ± 6.5 | ||||
BMI (kg/m2) | 28.9 ± 3.3 | ||||
Weight (kg) | 86.4 ± 15.1 | ||||
SBP (mmHg) | 133 ± 13 | ||||
DBP (mmHg) | 83 ± 8 | ||||
Fasting plasma glucose (mmol/L) | 7.2 ± 0.90 | ||||
Triglycerides (mmol/L) | 2.02 ± 1.33 | ||||
Cholesterol (mmol/L) | 5.22 ± 1.19 | ||||
HDL cholesterol (mmol/L) | 1.19 ± 0.36 | ||||
LDL cholesterol (mmol/L) | 3.13 ± 1.01 | ||||
Diabetes duration (years) | 5 ± 4 | ||||
Daily metformin dose (mg) | 1336 ± 599 | ||||
HbA1c, mmol/mol (%) | 51 ± 7 (6.8 ± 2.8) | ||||
ACE inhibitors, n (%) | 4 (28.6) | ||||
Angiotensin-II receptor antagonists, n (%) | 5 (35.7) | ||||
Calcium antagonists, n (%) | 3 (21.4) | ||||
Diuretics, n (%) | 1 (7.1) | ||||
Statins, n (%) | 4 (28.6) |
miRNAs expressions | |||||
|---|---|---|---|---|---|
miRNAs | Before euglycaemic clamp | Before hypoglycaemic clamp | 1-day after hypoglycaemic | 7-day after hypoglycaemic | P value |
miR-106a-5p | 5.56 [5.14–6.79] | 5.51 [4.81–7.69] | 6.61 [5.97–7.69] | 7.95 [6.40–8.19] | 0.126 |
miR-15b | 5.77 [5.32–6.90] | 5.48 [5.28–8.94] | 8.03 [7.04–8.64] | 8.13 [6.67–8.85] | 0.026 |
miR-15a | 7.27 [7.07–7.63] | 7.25 [6.45–7.63] | 7.49 [7.39–7.72] | 7.93 [7.21–8.11] | 0.009 |
miR-16-5p | 7.17 [6.71–7.52] | 6.94 [6.36–7.85] | 7.52 [7.43–7.71] | 7.65 [7.23–8.34] | 0.016 |
miR-223 | 7.32 [6.70–7.58] | 6.99 [6.43–7.32] | 7.74 [7.41–8.11] | 8.12 [7.80–8.60] | 0.002 |
miR-126 | 6.48 [5.90–6.66] | 6.46 [5.96–6.91] | 6.80 [6.56–7.78] | 7.09 [6.59–7.64] | 0.003 |
miR-129–2-3p | 5.53 [5.41–5.65] | 5.35 [5.14–5.54] | 5.38 [5.27–5.58] | 5.47 [5.22–5.60] | 0.789 |
miR-92a-3p | 5.90 [5.61–6.15] | 5.91 [5.65–6.20] | 5.73 [5.59–6.01] | 5.91 [5.70–6.11] | 0.473 |
miR-34a-5p | 5.37 [5.11–5.55] | 5.18 [4.82–5.38] | 5.18 [5.18–6.47] | 5.42 [5.31–6.21] | 0.443 |